[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jasper Therapeutics Inc. (JSPR)

Jasper Therapeutics Inc. (JSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,046
  • Shares Outstanding, K 27,997
  • Annual Sales, $ 0 K
  • Annual Income, $ -75,800 K
  • EBIT $ -55 M
  • EBITDA $ -54 M
  • 60-Month Beta 3.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.69
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.07
  • Most Recent Earnings $-0.24 on 08/14/26
  • Next Earnings Date 11/09/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 309.99% (-146.39%)
  • Historical Volatility 121.69%
  • IV Percentile 38%
  • IV Rank 25.26%
  • IV High 1,004.86% on 07/09/26
  • IV Low 75.16% on 03/03/26
  • Expected Move (DTE 24) 0.2465 (34.12%)
  • Put/Call Vol Ratio 1.45
  • Today's Volume 590
  • Volume Avg (30-Day) 152
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 2,975
  • Open Int (30-Day) 3,316
  • Expected Range 0.4759 to 0.9689

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.16
  • Number of Estimates 4
  • High Estimate $0.16
  • Low Estimate $-0.40
  • Prior Year $-1.13
  • Growth Rate Est. (year over year) +85.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5502 +31.30%
on 07/31/26
0.9700 -25.53%
on 08/11/26
+0.0340 (+4.94%)
since 07/24/26
3-Month
0.3151 +129.26%
on 06/29/26
1.0300 -29.86%
on 07/17/26
-0.1806 (-20.00%)
since 05/22/26
52-Week
0.3151 +129.26%
on 06/29/26
3.0000 -75.92%
on 08/25/25
-2.2076 (-75.34%)
since 08/22/25

Most Recent Stories

More News
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders  Completed a concurrent...

JSPR : 0.7224 (+0.89%)
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders  Concurrent $132 million private investment...

JSPR : 0.7224 (+0.89%)
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody...

JSPR : 0.7224 (+0.89%)
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody...

JSPR : 0.7224 (+0.89%)
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody...

JSPR : 0.7224 (+0.89%)
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody...

JSPR : 0.7224 (+0.89%)
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points  75% of CSU participants (n=36) enrolled in the open...

JSPR : 0.7224 (+0.89%)
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

Thomas Wiggans appointed Executive Chairperson  Jasper to host an investor webinar on January 8 th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension...

JSPR : 0.7224 (+0.89%)
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from...

JSPR : 0.7224 (+0.89%)
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab,...

JSPR : 0.7224 (+0.89%)

Business Summary

Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 0.8091
2nd Resistance Point 0.7722
1st Resistance Point 0.7473
Last Price 0.7224
1st Support Level 0.6855
2nd Support Level 0.6486
3rd Support Level 0.6237

See More

52-Week High 3.0000
Fibonacci 61.8% 1.9744
Fibonacci 50% 1.6575
Fibonacci 38.2% 1.3407
Last Price 0.7224
52-Week Low 0.3151

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.